These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 24937456)
1. GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy? Field MG; Harbour JW Cancer Cell; 2014 Jun; 25(6):714-5. PubMed ID: 24937456 [TBL] [Abstract][Full Text] [Related]
2. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515 [TBL] [Abstract][Full Text] [Related]
3. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516 [TBL] [Abstract][Full Text] [Related]
4. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651 [TBL] [Abstract][Full Text] [Related]
5. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Griewank KG; van de Nes J; Schilling B; Moll I; Sucker A; Kakavand H; Haydu LE; Asher M; Zimmer L; Hillen U; Thompson JF; Scolyer RA; Schadendorf D; Murali R Mod Pathol; 2014 Feb; 27(2):175-83. PubMed ID: 23887304 [TBL] [Abstract][Full Text] [Related]
6. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan. Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732 [TBL] [Abstract][Full Text] [Related]
9. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas. Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985 [TBL] [Abstract][Full Text] [Related]
10. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Zhang GM; Huang SS; Ye LX; Liu XL; Shi WH; Ren ZL; Zhou RH; Zhang JJ; Pan JX; Liu SW; Yu L; Li YL Pharmacol Res; 2022 Oct; 184():106464. PubMed ID: 36162600 [TBL] [Abstract][Full Text] [Related]
13. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163 [TBL] [Abstract][Full Text] [Related]
14. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597 [TBL] [Abstract][Full Text] [Related]
15. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540 [TBL] [Abstract][Full Text] [Related]
16. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma. Gaffal E J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611 [TBL] [Abstract][Full Text] [Related]
17. Mutations in GNA11 in uveal melanoma. Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380 [TBL] [Abstract][Full Text] [Related]
18. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Vader MJC; Madigan MC; Versluis M; Suleiman HM; Gezgin G; Gruis NA; Out-Luiting JJ; Bergman W; Verdijk RM; Jager MJ; van der Velden PA Br J Cancer; 2017 Sep; 117(6):884-887. PubMed ID: 28809862 [TBL] [Abstract][Full Text] [Related]
19. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Musi E; Ambrosini G; de Stanchina E; Schwartz GK Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540 [TBL] [Abstract][Full Text] [Related]
20. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Dono M; Angelini G; Cecconi M; Amaro A; Esposito AI; Mirisola V; Maric I; Lanza F; Nasciuti F; Viaggi S; Gualco M; Bandelloni R; Truini M; Coviello DA; Zupo S; Mosci C; Pfeffer U Br J Cancer; 2014 Feb; 110(4):1058-65. PubMed ID: 24423917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]